Journal Home > Volume 4 , Issue 1
Journal of Neurorestoratology 2016, 4(1): 79-83 https://doi.org/10.2147/JN.S119874
Review | Open Access | Issue | Published: 10 November 2016

Mesenchymal stromal cell therapy in ischemic stroke

Show Author's Information Ye Zhang,  Hong Deng,  Chao Pan,  Yang Hu,  Qian Wu,  Na Liu,  Zhouping Tang( )
Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of China
Keywords:
stroke, exosomes, therapy, transplantation, mesenchymal stromal cell
Cite this article:
Zhang Y, Deng H, Pan C, et al. Mesenchymal stromal cell therapy in ischemic stroke. Journal of Neurorestoratology, 2016, 4(1): 79-83. https://doi.org/10.2147/JN.S119874
Download citation
EndNote(RIS)
BibTeX

527

Views

12

Downloads

Citations

4

Crossref

3

WoS

0

Scopus

N/A

CSCD

Abstract Full text About this article

Stroke is a clinical disease with high incidence, high disability rate, and high mortality. But effective and safe therapy for stroke remains limited. Adult mesenchymal stromal cells (MSCs) perform a variety of therapeutic functions. MSC delivery improves neurological outcomes in ischemic stroke models via neurorestorative and neuroprotective effects such as angiogenic effects, promoting endogenous proliferation, and reducing apoptosis and inflammation. MSC secretome also showed powerful therapeutic effects as a cell-based therapy in animal experiments. Several clinical trials on MSC implantation via different routes have now been completed in patients with stroke. Although challenges such as immunogenicity of allo-MSCs and large-scale production strategies need to be overcome, MSCs can be considered as a promising potential therapy for ischemic stroke.


menu
Abstract
Full text
Outline
About this article

Mesenchymal stromal cell therapy in ischemic stroke

Show Author's information Ye Zhang, Hong Deng, Chao Pan, Yang Hu, Qian Wu, Na Liu, Zhouping Tang( )
Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of China

Abstract

Stroke is a clinical disease with high incidence, high disability rate, and high mortality. But effective and safe therapy for stroke remains limited. Adult mesenchymal stromal cells (MSCs) perform a variety of therapeutic functions. MSC delivery improves neurological outcomes in ischemic stroke models via neurorestorative and neuroprotective effects such as angiogenic effects, promoting endogenous proliferation, and reducing apoptosis and inflammation. MSC secretome also showed powerful therapeutic effects as a cell-based therapy in animal experiments. Several clinical trials on MSC implantation via different routes have now been completed in patients with stroke. Although challenges such as immunogenicity of allo-MSCs and large-scale production strategies need to be overcome, MSCs can be considered as a promising potential therapy for ischemic stroke.

Keywords: stroke, exosomes, therapy, transplantation, mesenchymal stromal cell

References(41)

1.
Majid A. Neuroprotection in stroke: past, present, and future. ISRN Neurol. 2014;2014:515716.
DOI Google Scholar
2.
Greco SJ, Corcoran KE, Cho KJ, Rameshwar P. Tachykinins in the emerging immune system: relevance to bone marrow homeostasis and maintenance of hematopoietic stem cells. Front Biosci. 2004;9:1782-1793.
DOI Google Scholar
3.
Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-317.
DOI Google Scholar
4.
Trounson A, McDonald C. Stem cell therapies in clinical trials: progress and challenges. Cell Stem Cell. 2015;17(1):11-22.
DOI Google Scholar
5.
Aleynik A, Gernavage KM, Mourad Y, et al. Stem cell delivery of therapies for brain disorders. Clin Transl Med .2014;3:24.
DOI Google Scholar
6.
Liu L, Eckert MA, Riazifar H, Kang DK, Agalliu D, Zhao W. From blood to the brain: can systemically transplanted mesenchymal stem cells cross the blood-brain barrier? Stem Cells Int. 2013;2013:435093.
DOI Google Scholar
7.
Zhao Y, Wang X, Dong P, et al. Bone marrow derived mesenchymal stem cells alleviated brain injury via down-regulation of interleukin-1beta in focal cerebral ischemic rats. Am J Transl Res. 2016;8(3):1541-1550.
Google Scholar
8.
Kim S, Chang KA, Kim J, et al. The preventive and therapeutic effects of intravenous human adipose-derived stem cells in Alzheimer’s disease mice. PLoS One. 2012;7(9):e45757.
DOI Google Scholar
9.
Pirzad Jahromi G, Shabanzadeh Pirsaraei A, Sadr SS, et al. Multipotent bone marrow stromal cell therapy promotes endogenous cell proliferation following ischemic stroke. Clin Exp Pharmacol Physiol. 2015;42(11):1158-1167.
DOI Google Scholar
10.
Li Y, Chen J, Chen XG, et al. Human marrow stromal cell therapy for stroke in rat: neurotrophins and functional recovery. Neurology. 2002;59(4):514-523.
DOI Google Scholar
11.
Horita Y, Honmou O, Harada K, Houkin K, Hamada H, Kocsis JD. Intravenous administration of glial cell line-derived neurotrophic factor gene-modified human mesenchymal stem cells protects against injury in a cerebral ischemia model in the adult rat. J Neurosci Res. 2006;84(7):1495-1504.
DOI Google Scholar
12.
Chung TN, Kim JH, Choi BY, Chung SP, Kwon SW, Suh SW. Adipose-derived mesenchymal stem cells reduce neuronal death after transient global cerebral ischemia through prevention of blood-brain barrier disruption and endothelial damage. Stem cells Transl Med. 2015;4(2):178-185.
DOI Google Scholar
13.
Moisan A, Favre I, Rome C, et al. Intravenous injection of clinical grade human MSCs after experimental stroke: functional benefit and microvascular effect. Cell Transplant. Epub 2016 Feb 26.
Google Scholar
14.
Zhang LL, Zhang HT, Cai YQ, et al. Anti-inflammatory effect of mesenchymal stromal cell transplantation and quercetin treatment in a rat model of experimental cerebral ischemia. Cell Mol Neurobiol. 2016;36(7):1023-1034.
DOI Google Scholar
15.
Lee SH, Jin KS, Bang OY, et al. Differential migration of mesenchymal stem cells to ischemic regions after middle cerebral artery occlusion in rats. PLoS One. 2015;10(8):e0134920.
DOI Google Scholar
16.
Zhang L, Li Y, Zhang C, Chopp M, Gosiewska A, Hong K. Delayed administration of human umbilical tissue-derived cells improved neurological functional recovery in a rodent model of focal ischemia. Stroke. 2011;42(5):1437-1444.
DOI Google Scholar
17.
Shin TH, Phukan G, Shim JS, et al. Restoration of polyamine metabolic patterns in in vivo and in vitro model of ischemic stroke following human mesenchymal stem cell treatment. Stem Cells Int. 2016;2016:4612531.
DOI Google Scholar
18.
Cheng Q, Zhang Z, Zhang S, et al. Human umbilical cord mesenchymal stem cells protect against ischemic brain injury in mouse by regulating peripheral immunoinflammation. Brain Res. 2015;1594:293-304.
DOI Google Scholar
19.
Tang G, Liu Y, Zhang Z, et al. Mesenchymal stem cells maintain blood-brain barrier integrity by inhibiting aquaporin-4 upregulation after cerebral ischemia. Stem Cells. 2014;32(12):3150-3162.
DOI Google Scholar
20.
Jeong CH, Kim SM, Lim JY, Ryu CH, Jun JA, Jeun SS. Mesenchymal stem cells expressing brain-derived neurotrophic factor enhance endogenous neurogenesis in an ischemic stroke model. BioMed Res Int. 2014;2014:129145.
DOI Google Scholar
21.
Yu X, Chen D, Zhang Y, et al. Overexpression of CXCR4 in mesenchymal stem cells promotes migration, neuroprotection and angiogenesis in a rat model of stroke. J Neurol Sci. 2012;316(1-2):141-149.
DOI Google Scholar
22.
Lu H, Liu X, Zhang N, et al. Neuroprotective effects of brain-derived neurotrophic factor and noggin-modified bone mesenchymal stem cells in focal cerebral ischemia in rats. J Stroke Cerebrovasc Dis. 2016;25(2):410-418.
DOI Google Scholar
23.
Wei N, Yu SP, Gu X, et al. Delayed intranasal delivery of hypoxic-preconditioned bone marrow mesenchymal stem cells enhanced cell homing and therapeutic benefits after ischemic stroke in mice. Cell Transplant. 2013;22(6):977-991.
DOI Google Scholar
24.
Crisostomo PR, Wang Y, Markel TA, Wang M, Lahm T, Meldrum DR. Human mesenchymal stem cells stimulated by TNF-alpha, LPS, or hypoxia produce growth factors by an NF kappa B- but not JNK-dependent mechanism. Am J Physiol Cell Physiol .2008;294(3):C675-C682.
DOI Google Scholar
25.
Lopatina T, Kalinina N, Karagyaur M, et al. Adipose-derived stem cells stimulate regeneration of peripheral nerves: BDNF secreted by these cells promotes nerve healing and axon growth de novo. PLoS One. 2011;6(3):e17899.
DOI Google Scholar
26.
Zhao Q, Hu J, Xiang J, et al. Intranasal administration of human umbilical cord mesenchymal stem cells-conditioned medium enhances vascular remodeling after stroke. Brain Res. 2015;1624:489-496.
DOI Google Scholar
27.
Huang W, Lv B, Zeng H, et al. Paracrine factors secreted by MSCs promote astrocyte survival associated with GFAP downregulation after ischemic stroke via p38 MAPK and JNK. J Cell Physiol. 2015;230(10):2461-2475.
DOI Google Scholar
28.
Tsai MJ, Tsai SK, Hu BR, et al. Recovery of neurological function of ischemic stroke by application of conditioned medium of bone marrow mesenchymal stem cells derived from normal and cerebral ischemia rats. J Biomed Sci. 2014;21:5.
DOI Google Scholar
29.
Webber J, Clayton A. How pure are your vesicles? J Extracell Vesicles. 2013;2:1-6.
DOI Google Scholar
30.
Zhang Y, Chopp M, Meng Y, et al. Effect of exosomes derived from multipluripotent mesenchymal stromal cells on functional recovery and neurovascular plasticity in rats after traumatic brain injury. J Neurosurg. 2015;122(4):856-867.
DOI Google Scholar
31.
Yang T, Martin P, Fogarty B, et al. Exosome delivered anticancer drugs across the blood-brain barrier for brain cancer therapy in Danio rerio. Pharm Res. 2015;32(6):2003-2014.
DOI Google Scholar
32.
Xin H, Li Y, Chopp M. Exosomes/miRNAs as mediating cell-based therapy of stroke. Front Cell Neurosci. 2014;8:377.
DOI Google Scholar
33.
Jiang Y, Zhu W, Zhu J, Wu L, Xu G, Liu X. Feasibility of delivering mesenchymal stem cells via catheter to the proximal end of the lesion artery in patients with stroke in the territory of the middle cerebral artery. Cell Transplant. 2013;22(12):2291-2298.
DOI Google Scholar
34.
Lee JS, Hong JM, Moon GJ, Lee PH, Ahn YH, Bang OY; STARTING collaborators. A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. Stem Cells. 2010;28(6):1099-1106.
DOI Google Scholar
35.
Qiao LY, Huang FJ, Zhao M, et al. A two-year follow-up study of cotransplantation with neural stem/progenitor cells and mesenchymal stromal cells in ischemic stroke patients. Cell Transplant. 2014;23 (Suppl 1):S65-S72.
DOI Google Scholar
36.
Honmou O, Houkin K, Matsunaga T, et al. Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in stroke. Brain. 2011;134(Pt 6):1790-1807.
DOI Google Scholar
37.
Steinberg GK, Kondziolka D, Wechsler LR, et al. Clinical outcomes of transplanted modified bone marrow-derived mesenchymal stem cells in stroke: a phase 1/2a study. Stroke. 2016;47(7):1817-1824.
DOI Google Scholar
38.
Zangi L, Margalit R, Reich-Zeliger S, et al. Direct imaging of immune rejection and memory induction by allogeneic mesenchymal stromal cells. Stem Cells. 2009;27(11):2865-2874.
DOI Google Scholar
39.
Nauta AJ, Westerhuis G, Kruisselbrink AB, Lurvink EG, Willemze R, Fibbe WE. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood. 2006;108(6):2114-2120.
DOI Google Scholar
40.
Grinnemo KH, Mansson A, Dellgren G, et al. Xenoreactivity and engraftment of human mesenchymal stem cells transplanted into infarcted rat myocardium. J Thorac Cardiovasc Surg. 2004;127(5):1293-1300.
DOI Google Scholar
41.
Lee KC, Lin HC, Huang YH, Hung SC. Allo-transplantation of mesenchymal stem cells attenuates hepatic injury through IL1Ra dependent macrophage switch in a mouse model of liver disease. J Hepatol. 2015;63(6):1405-1412.
DOI Google Scholar
Publication history
Copyright
Acknowledgements
Rights and permissions

Publication history

Published: 10 November 2016
Issue date: December 2016

Copyright

© 2016 The Author(s).

Acknowledgements

This project was supported by grants from the National Natural Sciences Foundation of China (No. JX4A03 and No. 81471201)

Rights and permissions

© 2016 Zhang et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

Return